



**DATE: June 17, 2020**

**Case #: WA 265207**

**Via Electronic Mail**

Dr. Danny M. Barnes  
President and CPO  
Triangle Compounding Pharmacy, Inc.  
3700 Regency Pkwy, Suite 140  
Cary, NC 27518-8696

Dear Dr. Barnes:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Triangle Compounding Pharmacy, Inc., located at 3700 Regency Pkwy, Ste 140 Cary, NC 27518 (Pharmacy license #13129) from March 26, 2019, to April 4, 2019, by the U.S. Food and Drug Administration (FDA).

When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

Page 2 – Dr. Danny M. Barnes, President and CPO  
Triangle Compounding Pharmacy, Inc., Cary, NC  
June 17, 2020

If you have any questions about the released information, please contact Rebecca Asente, Compliance Officer, at 504-846-6104, or by email at [Rebecca.Asente@fda.hhs.gov](mailto:Rebecca.Asente@fda.hhs.gov).

Sincerely,

Mark W. Rivero -S

Digitally signed by Mark W. Rivero -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=Mark W. Rivero -S,  
0.9.2342.19200300.100.1.1=1300060122  
Date: 2020.06.17 10:54:06 -05'00'

For John W. Diehl, M.S  
Director, Compliance Branch  
Office of Pharmaceutical Quality Operations,  
Division II

Enclosure: EIR

Cc: Jay Campbell (**cover letter only**)  
Executive Director  
North Carolina Board of Pharmacy  
6015 Farrington Road  
Suite 201  
Chapel Hill, North Carolina 27517